Public Protocol
Platform

Paper

Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease

External resource. Not made or verified by Public Protocol.

NEJM 2025 report of a customised base-editing therapy for one infant with CPS1 deficiency; the authors state longer follow-up is needed.

Go to the source

https://doi.org/10.1056/NEJMoa2504747

Maintainer
Musunuru and colleagues
Licence, as stated at its source
Not stated on the page opened
Open or commercial
Not stated by the maker
Maturity
PrototypeOur reading, 16 November 2026
Safety
S3medical
Review
Listed 16 November 2026by Public Protocol editors
Checked
16 November 2026
Next check due
16 May 2027
Steward
Public Protocol editors

Where it sits in the blueprint

Stages

Learn

Elements it supports

Recorded when its maker or a reviewer places it against single elements.

Context

Climate, setting, scale, cost and skill: not stated in this entry. Check the source against your own place and numbers.

Verification

No verification is recorded on Public Platform for this entry. Records are added when someone reads it for accuracy, reviews it with a stated qualification, builds it or measures it.

Record

How it came in

Seed catalogue, 16 November 2026. Listed from Praecise open research. The source was opened and described on the date shown.

Licence

Not stated on the page opened. Read at https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:40373211%20AND%20SRC:MED&resultType=core&format=json. How licences are recorded